Aspirin may help some breast cancer survivors, but changes in DNA may mean harm for others

Chemical changes in DNA -- called methylation -- in blood and breast cancer tumors may modify aspirin's role in mortality risk.


Past investigations have demonstrated that a few ladies who use aspirin and are later diagnosed with breast cancer growth may live longer, which might be identified with the medication’s mitigating impacts on the body. Notwithstanding, a portion of aspirin users with breast cancer seemed to have a higher risk of mortality following breast cancer.

Now a new study by the analysts at the University of North Carolina at Chapel Hill Gillings School of Global Public Health, the reason behind this reverse effect could be clarified by DNA methylation of genes in breast cancer tumors or peripheral blood.

Methylation is a chemical modification wherein a methyl group acts like light switches along with the DNA particle, turning some genetic activity on and some off. Chemical shifts in areas of DNA that are in charge of cell demise, damage, and repair-, for example, happens in methylation – are known supporters of the improvement of cancer after some time. Recognizing the zones where these epigenetic changes happen show guarantee in foreseeing certain risks or effective strategies for treatment.

This is the first study to determine the effect of DNA methylation in breast tumor tissues and cells circulating in the patients’ peripheral blood on the association between aspirin use and mortality in women with breast cancer.

First author Tengteng Wang, who led this study while she was a doctoral candidate in the epidemiology department at the Gillings School said, “Chronic inflammation is a key player in the development of multiple cancer types, including breast cancer. Aspirin is a major non-steroidal anti-inflammatory drug which has anti-inflammatory properties. Given this, substantial evidence from laboratory and population studies suggests that taking aspirin may reduce the risk of developing breast cancer.”

Be that as it may, the relationship of aspirin use with death results following breast cancer diagnosis stays uncertain and conflicting crosswise over examinations, which incited the scientists to investigate whether aspirin’s varying impacts on breast cancer patients could be identified with different DNA profiles because of methylation.

The group analyzed information from 1,266 ladies with breast cancer in the Long Island Breast Cancer Study who were pursued subsequent mortality. All-cause mortality after breast cancer growth was raised by 67% among the individuals who had utilized aspirin at least once a week for six weeks for about a month and a half pre-diagnosis and had a methylated tumor promotor of breast cancer gene 1, known as BRCA1.

Breast cancer explicit mortality diminished by 22-40% in aspirin users with unmethylated tumor advertiser of BRCA1 and progesterone receptor (PR) genes, and furthermore those with long interspersed elements- 1 global hypermethylation. These outcomes propose genuine contrasts in breast cancer mortality risk in patient groups with these distinctive methylation profiles in tumor tissue DNA and fringe blood DNA.

Scientists also highlight the need for further exploration of the potential impact – good or bad – aspirin may have on specific breast cancer patients due to their DNA methylation profiles.

Wang and her mentor Marilie Gammon, a professor of epidemiology at the Gillings School and senior author on the study said, “Future research designed to replicate our findings should include a larger sample size to allow examination of patterns of aspirin use, and an enlarged panel of genes to explore the role of genetic predisposition in driving overall genetic instability on survival after breast cancer diagnosis.”


See stories of the future in your inbox each morning.